Comparison of Sarcopenia in Diabetics and Non-Diabetics: Prevalence and Impact on Muscle Health.

Authors

  • Dr. Farhana Ahad Author
  • Dr. Mahrukh Malik Author
  • Dr. Masarat Nazeer Author

Keywords:

Sarcopenia, T2DM, Muscle Strength, Insulin Resistance, Gait Speed, Handgrip Strength, Metabolic Dysfunction, Physical Performance, Aging, Neuromuscular Dysfunction.

Abstract

A gradual reduction in muscle mass, strength and function over time, known as sarcopenia, is a growing concern among patients who are presenting with type 2 diabetes mellitus (T2DM). Rapid muscle loss may be associated with insulin resistance, chronic inflammation and oxidative stress that are associated with T2DM. This study aimed to assess the prevalence of sarcopenia in adult age group between 40-60 years and compare the association of sarcopenia in diabetic and non-diabetic adults. Methodology: The present comparative analysis was done at the Department of Physiology, SKIMS Medical College & Hospital, Srinagar, India for two years. About 136 participants were enrolled in this study, of them 68 had a diagnosis of T2DM (>5 years duration) and 68 were age matched controls. We assessed clinically relevant parameters such as body mass index, handgrip strength and gait speed. The criteria for the diagnosis of sarcopenia were applied. Results: The results revealed a significantly higher prevalence of sarcopenia among diabetics in comparison to non-diabetics (16.18% vs. 8.82%; p=0.039). The average BMI values were on higher side in the diabetics (27.15) as compared with the non-diabetics (25.46) with difference being statistically significant (p<0.05). Interestingly, the diabetics reflected significantly less handgrip strength than the non-diabetics (21.36 vs. 27.60) (p<0.01). Diabetics had a significantly higher gait speed (17.16 vs. 9.97) than non-diabetics (p<0.01). Women had higher prevalence rates, and there was a higher prevalence rate among those aged 51-60 years. Conclusion: Sarcopenia was associated with T2DM and changes in muscle strength and physical performance.

References

1. Dufour AB, Hannan MT, Murabito JM, et al. Sarcopenia definitions considering body size and fat mass are associated with mobility limitations: The Framingham Study. J GerontolABiol Sci Med Sci. 2012 doi: 10.1093/gerona/gls109. Epub ahead of print

2. Xue QL, Walston JD, Fried LP, Beamer BA. Prediction of risk of falling, physical disability, and frailty by rate of decline in grip strength: the women’s health and aging study. Arch Intern Med. 2011;171:1119–1121. doi: 10.1001/archinternmed.2011.252.

3. Marsh AP, Rejeski WJ, Espeland MA, et al. Muscle strength and BMI as predictors of major mobility disability in the Lifestyle Interventions and Independence for Elders pilot (LIFE-P) J GerontolABiol Sci Med Sci. 2011;66:1376–1383. doi: 10.1093/gerona/glr158

4. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010;39:412–423. doi: 10.1093/ageing/afq034.

5. Mesinovic J, Zengin A, De Courten B, Ebeling PR, Scott D. Sarcopenia and type 2 diabetes mellitus: a bidirectional relationship. Diabetes Metab Syndr Obes. 2019 Jul 8;12:1057-1072. doi: 10.2147/DMSO.S186600. PMID: 31372016; PMCID: PMC6630094.

6. Chen H, Huang X, Dong M, Wen S, Zhou L, Yuan X. The Association Between Sarcopenia and Diabetes: From Pathophysiology Mechanism to Therapeutic Strategy. Diabetes Metab Syndr Obes. 2023 May 30;16:1541-1554. doi: 10.2147/DMSO.S410834. PMID: 37275941; PMCID: PMC10239259.

7. Izzo A, Massimino E, Riccardi G, Della Pepa G. A Narrative Review on Sarcopenia in Type 2 Diabetes Mellitus: Prevalence and Associated Factors. Nutrients. 2021 Jan 9;13(1):183. doi: 10.3390/nu13010183. PMID: 33435310; PMCID: PMC7826709.

8. Yuan J, Jia P. Prediabetes and diabetes were attributed to the prevalence and severity of sarcopenia in middle-aged and elderly adults. DiabetolMetab Syndr 16, 122 (2024). https://doi.org/10.1186/s13098-024-01355-3

9. Papadopoulou SK. Sarcopenia: A Contemporary Health Problem among Older Adult Populations. Nutrients. 2020 May 1;12(5):1293. doi: 10.3390/nu12051293. PMID: 32370051; PMCID: PMC7282252.

10. Cohn SH, Vartsky D, Yasumura S, Sawitsky A, , Zanzi I, , Vaswani A, & Ellis KJ1980 Compartmental body composition based on total-body nitrogen, potassium, and calcium. American Journal of Physiology 239 E524–E530.

11. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, Cooper C, Landi F, Rolland Y, Sayer AA, Schneider SM, Sieber CC, Topinkova E, Vandewoude M, Visser M, Zamboni M; Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019 Jan 1;48(1):16-31. doi: 10.1093/ageing/afy169. Erratum in: Age Ageing. 2019 Jul 1;48(4):601. doi: 10.1093/ageing/afz046. PMID: 30312372; PMCID: PMC6322506.

12. Sravya SL, Swain J, Sahoo AK, Mangaraj S, Kanwar J, Jadhao P, Das S. Sarcopenia in Type 2 Diabetes Mellitus: Study of the Modifiable Risk Factors Involved. J Clin Med. 2023 Aug 24;12(17):5499. doi: 10.3390/jcm12175499. PMID: 37685565; PMCID: PMC10488216.

13. Gupta RD, Kothadia RJ, Parray AA. Association between abdominal obesity and diabetes in India: Findings from a nationally representative study. Diabetes Epidemiology and Management. 2023 Oct 1;12:100155.

14. Kalyani RR, Corriere M, Ferrucci L. Age-related and disease-related muscle loss: the effect of diabetes, obesity, and other diseases. Lancet Diabetes Endocrinol. 2014 Oct;2(10):819-29. doi: 10.1016/S2213-8587(14)70034-8. Epub 2014 Mar 6. PMID: 24731660; PMCID: PMC4156923.

15. Miljkovic-Gacic I, Gordon CL, Goodpaster BH, Bunker CH, Patrick AL, Kuller LH, Wheeler VW, Evans RW, Zmuda JM. Adipose tissue infiltration in skeletal muscle: age patterns and association with diabetes among men of African ancestry. The American journal of clinical nutrition. 2008 Jun 1;87(6):1590-5.

16. Pechmann LM, Jonasson TH, Canossa VS, Trierweiler H, Kisielewicz G, Petterle RR, Moreira CA, Borba VZ. Sarcopenia in type 2 diabetes mellitus: a cross‐sectional observational study. International journal of endocrinology. 2020;2020(1):7841390.

17. Cheung, B. M., & Li, C. (2012). Diabetes and hypertension: is there a common metabolic pathway? Current Atherosclerosis Reports, 14(2), 160-166.

18. Sumukadas D, Witham MD, Struthers AD, Mcmurdo ME. ACE inhibitors as a therapy for sarcopenia—evidence and possible mechanisms. The Journal of Nutrition Health and Aging. 2008 Sep;12:480-5.

19. Onder G, Penninx BW, Balkrishnan R, Fried LP, Chaves PH, Williamson J, Carter C, Di Bari M, Guralnik JM, Pahor M. Relation between use of angiotensin-converting enzyme inhibitors and muscle strength and physical function in older women: an observational study. The Lancet. 2002 Mar 16;359(9310):926-30.

20. Sravya SL, Swain J, Sahoo AK, Mangaraj S, Kanwar J, Jadhao P, Das S. Sarcopenia in Type 2 Diabetes Mellitus: Study of the Modifiable Risk Factors Involved. J Clin Med. 2023 Aug 24;12(17):5499. doi: 10.3390/jcm12175499. PMID: 37685565; PMCID: PMC10488216.

21. Henin G, Loumaye A, Leclercq IA, Lanthier N. Myosteatosis: Diagnosis, pathophysiology and consequences in metabolic dysfunction-associated steatotic liver disease. JHEP Rep. 2023 Nov 14;6(2):100963. doi: 10.1016/j.jhepr.2023.100963. PMID: 38322420; PMCID: PMC10844870.

22. Dial AG, Monaco CMF, Grafham GK, Romanova N, Simpson JA, Tarnopolsky MA, Perry CGR, Kalaitzoglou E, Hawke TJ. Muscle and serum myostatin expression in type 1 diabetes. Physiol Rep. 2020 Jul;8(13):e14500. doi: 10.14814/phy2.14500. PMID: 32652899; PMCID: PMC7354085.

23. Jun L, Robinson M, Geetha T, Broderick TL, Babu JR. Prevalence and Mechanisms of Skeletal Muscle Atrophy in Metabolic Conditions. Int J Mol Sci. 2023 Feb 3;24(3):2973. doi: 10.3390/ijms24032973. PMID: 36769296; PMCID: PMC9917738.

24. Giri B, Dey S, Das T, Sarkar M, Banerjee J, Dash SK. Chronic hyperglycemia mediated physiological alteration and metabolic distortion leads to organ dysfunction, infection, cancer progression and other pathophysiological consequences: an update on glucose toxicity. Biomedicine & pharmacotherapy. 2018 Nov 1;107:306-28.

25. Lecce E, Bellini A, Greco G, Martire F, Scotto di Palumbo A, Sacchetti M, Bazzucchi I. Physiological mechanisms of neuromuscular impairment in diabetes‐related complications: Can physical exercise help prevent it?. The Journal of Physiology. 2025.

Downloads

Published

2026-11-10

Similar Articles

1-10 of 68

You may also start an advanced similarity search for this article.